---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-192735"
form_type: "8-K"
ticker: "STOK"
cik: "0001623526"
company_name: "Stoke Therapeutics, Inc."
filed_at: "2023-07-25T23:59:59+00:00"
generated_at: "2026-06-13T03:09:34.166464+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# STK-001 70mg achieves 80% median convulsive seizure reduction at 3 months in Dravet syndrome

## Summary
- 70mg multiple-dose cohort (n=6): median convulsive seizure reduction 80% at 3 months, 89% at 6 months after last dose.
- 30mg and 45mg OLE data show durable seizure reductions and improvements in cognition/behavior per VABS-III and BRIEF-P.
- Safety: generally well-tolerated in 74 patients; one SUSAR attributed to drug; no treatment-related discontinuations.
- Additional Phase 1/2a end-of-study data and Phase 3 planning update expected in Q1 2024 and H1 2024 respectively.

## SEC filing metadata
- accession: 0001193125-23-192735
- form_type: 8-K
- ticker: STOK
- cik: 0001623526
- company_name: Stoke Therapeutics, Inc.
- filed_at: 2023-07-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1623526/000119312523192735/0001193125-23-192735-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1623526/000119312523192735/d530062d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-192735
- JSON: https://secwatch.observer/filing/0001193125-23-192735.json
- Plain text: https://secwatch.observer/filing/0001193125-23-192735.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.